The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas

Tim Illidge; Barbara Pro; Lorenz Trumper; Owen A O'Connor; Ranjana Advani; Swaminathan Iyer; Nancy L Bartlett; Jacob Haaber Christensen; Frank  Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Pier-Luigi Zinzani; Meredith Little; Thomas Manley; Shangbang Rao; Michelle Fanale; Steven Horwitz

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas

Tim Illidge, Barbara Pro, Lorenz Trumper, Owen A O'Connor, Ranjana Advani, Swaminathan Iyer, Nancy L Bartlett, Jacob Haaber Christensen, Frank Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Pier-Luigi ZinzaniMeredith Little, Thomas Manley, Shangbang Rao, Michelle Fanale, Steven Horwitz

KI, OUH, Forskningsenhed for Hæmatologi (Odense)

University Medical Center Göttingen

Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

Originalsprog	Engelsk
Publikationsdato	15. jun. 2019
Status	Udgivet - 15. jun. 2019
Begivenhed	24th European Hematology Association Congress (EHA) - Amsterdam, Holland Varighed: 13. jun. 2019 → 16. jun. 2019

Konference

Konference	24th European Hematology Association Congress (EHA)
Land/Område	Holland
By	Amsterdam
Periode	13/06/2019 → 16/06/2019

Dokumenter og links

https://library.ehaweb.org/eha/2019/24th/266687/tim.illidge.the.echelon-2.trial.results.of.a.randomized.double-blind.phase.3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1070

Citationsformater

Illidge, T., Pro, B., Trumper, L., O'Connor, O. A., Advani, R., Iyer, S., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., ... Horwitz, S. (2019). The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas. Poster session præsenteret på 24th European Hematology Association Congress (EHA), Amsterdam, Holland. https://library.ehaweb.org/eha/2019/24th/266687/tim.illidge.the.echelon-2.trial.results.of.a.randomized.double-blind.phase.3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1070

Illidge, Tim ; Pro, Barbara ; Trumper, Lorenz et al. / The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas. Poster session præsenteret på 24th European Hematology Association Congress (EHA), Amsterdam, Holland.

@conference{5dee6ce1fe624c0f8bf6f8ec6066dc1f,

title = "The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas",

author = "Tim Illidge and Barbara Pro and Lorenz Trumper and O'Connor, {Owen A} and Ranjana Advani and Swaminathan Iyer and Bartlett, {Nancy L} and Christensen, {Jacob Haaber} and Frank Morschhauser and Eva Domingo-Domenech and Giuseppe Rossi and Kim, {Won Seog} and Tatyana Feldman and Anne Lennard and David Belada and {\'A}rp{\'a}d Ill{\'e}s and Kensei Tobinai and Kunihiro Tsukasaki and Su-Peng Yeh and Pier-Luigi Zinzani and Meredith Little and Thomas Manley and Shangbang Rao and Michelle Fanale and Steven Horwitz",

year = "2019",

month = jun,

day = "15",

language = "English",

note = "24th European Hematology Association Congress (EHA) ; Conference date: 13-06-2019 Through 16-06-2019",

}

Illidge, T, Pro, B, Trumper, L, O'Connor, OA, Advani, R, Iyer, S, Bartlett, NL, Christensen, JH, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, WS, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Zinzani, P-L, Little, M, Manley, T, Rao, S, Fanale, M & Horwitz, S 2019, 'The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas', 24th European Hematology Association Congress (EHA), Amsterdam, Holland, 13/06/2019 - 16/06/2019. <https://library.ehaweb.org/eha/2019/24th/266687/tim.illidge.the.echelon-2.trial.results.of.a.randomized.double-blind.phase.3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1070>

The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas. / Illidge, Tim; Pro, Barbara; Trumper, Lorenz et al.
2019. Poster session præsenteret på 24th European Hematology Association Congress (EHA), Amsterdam, Holland.

Publikation: Konferencebidrag uden forlag/tidsskrift › Poster › Forskning › peer review

TY - CONF

T1 - The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas

AU - Illidge, Tim

AU - Pro, Barbara

AU - Trumper, Lorenz

AU - O'Connor, Owen A

AU - Advani, Ranjana

AU - Iyer, Swaminathan

AU - Bartlett, Nancy L

AU - Christensen, Jacob Haaber

AU - Morschhauser, Frank

AU - Domingo-Domenech, Eva

AU - Rossi, Giuseppe

AU - Kim, Won Seog

AU - Feldman, Tatyana

AU - Lennard, Anne

AU - Belada, David

AU - Illés, Árpád

AU - Tobinai, Kensei

AU - Tsukasaki, Kunihiro

AU - Yeh, Su-Peng

AU - Zinzani, Pier-Luigi

AU - Little, Meredith

AU - Manley, Thomas

AU - Rao, Shangbang

AU - Fanale, Michelle

AU - Horwitz, Steven

PY - 2019/6/15

Y1 - 2019/6/15

M3 - Poster

T2 - 24th European Hematology Association Congress (EHA)

Y2 - 13 June 2019 through 16 June 2019

ER -

Illidge T, Pro B, Trumper L, O'Connor OA, Advani R, Iyer S et al.. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas. 2019. Poster session præsenteret på 24th European Hematology Association Congress (EHA), Amsterdam, Holland.